Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions

被引:37
作者
Chorny, JA
Barr, RJ [1 ]
Kyshtoobayeva, A
Jakowatz, J
Reed, RJ
机构
[1] Univ Calif Irvine, Ctr Med, Dermatopathol Lab, Orange, CA 92868 USA
[2] Univ Calif Irvine, Ctr Med, Dept Surg, Orange, CA USA
[3] Oncotech, Irvine, CA USA
[4] Reed Pathol Lab, New Orleans, LA USA
关键词
compound nevus; MIB-1 (Ki-67) antibody; minimal deviation melanoma; p53; protein; Spitz nevus; skin; superficial spreading malignant melanoma;
D O I
10.1097/01.MP.0000072747.08404.38
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Minimal deviation melanoma is a controversial entity encompassing a heterogeneous group of lesions cytologically in the spectrum between recognized subtypes of nevi and conventional "primary configuration" melanomas and reported to have a better prognosis than the latter. To evaluate the distinctiveness of minimal deviation melanoma, Ki-67 proliferation rates and p53 expression in minimal deviation melanomas were compared with those in compound nevi, Spitz nevi, and vertical growth phase superficial spreading malignant melanoma. Twelve examples of each lesion were immunostained with antibodies to the Ki-67 and p53 proteins and evaluated by a pathologist who was blind to the diagnoses. The mean Ki-67 (MIB-1) proliferation rates for the compound nevi, Spitz nevi, minimal deviation melanomas, and superficial spreading malignant melanomas were 0, 3%, 13%, and 25%, respectively. The mean Ki-67 proliferation rate was statistically greater in the minimal deviation melanomas than in the compound nevi or the Spitz nevi (P < .05), but the proliferation rates in the two melanoma subtypes were not statistically significant (P = .08). The mean p53 values for these lesions were 0, 9%, 9%, and 26%, respectively; the latter two were statistically different (P < .01). Based on these Ki-67 and p53 immunophenotypes, minimal deviation melanoma may represent a distinct entity.
引用
收藏
页码:525 / 529
页数:5
相关论文
共 18 条
[1]  
Bastian BC, 1998, CANCER RES, V58, P2170
[2]   Immunohistochemical study of p53 protein expression in Spitz nevus as compared with other melanocytic lesions [J].
Bergman, R ;
Shemer, A ;
Levy, R ;
FriedmanBirnbaum, R ;
Trau, H ;
Lichtig, C .
AMERICAN JOURNAL OF DERMATOPATHOLOGY, 1995, 17 (06) :547-550
[3]   P53 MUTATIONS ARE COMMON AND EARLY EVENTS THAT PRECEDE TUMOR INVASION IN SQUAMOUS-CELL NEOPLASIA OF THE SKIN [J].
CAMPBELL, C ;
QUINN, AG ;
RO, YS ;
ANGUS, B ;
REES, JL .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1993, 100 (06) :746-748
[4]   P53 PROTEIN EXPRESSION IN NEVI AND MELANOMAS [J].
CRISTOFOLINI, M ;
BOI, S ;
GIRLANDO, S ;
ZUMIANI, G ;
CRISTOFOLINI, P ;
PALMA, PD ;
DOGLIONI, C ;
BARBARESCHI, M .
ARCHIVES OF DERMATOLOGY, 1993, 129 (06) :739-743
[5]  
Elder David, 1997, P625
[6]   PROLIFERATIVE ACTIVITY IN SPITZ NEVI COMPARED WITH OTHER MELANOCYTIC SKIN-LESIONS [J].
HOFMANNWELLENHOF, R ;
RIEGER, E ;
SMOLLE, J ;
KERL, H .
MELANOMA RESEARCH, 1993, 3 (05) :313-317
[7]   Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: An adjunct for recognition of the vertical growth phase in malignant melanomas? [J].
Kaleem, Z ;
Lind, AC ;
Humphrey, PA ;
Sueper, RH ;
Swanson, PE ;
Ritter, JH ;
Wick, MR .
MODERN PATHOLOGY, 2000, 13 (03) :217-222
[8]  
KanterLewensohn L, 1997, MODERN PATHOL, V10, P917
[9]  
KORABIOWSKA M, 1995, ANTICANCER RES, V15, P885
[10]  
LeBoit P E, 1997, Adv Dermatol, V13, P289